<!DOCTYPE html>
<html>
    <head>
        <title>US-SXR-CNS-Efficacy-in-BPD</title>
        <meta charset="UTF-8">
        <meta name="format-detection" content="telephone=no" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no">
        <link rel='stylesheet' href='../shared/assets/css/style.css' />
        <link rel='stylesheet' href='../shared/assets/css/reveal.css' />
        <link rel='stylesheet' href='../shared/assets/css/footer.css' />

        <script type="text/javascript" src="../shared/assets/js/jquery-1.11.1.min.js"></script>

    </head>
    <body id="EfficacyinBPD" class="dosing-bpd template-2">

        <div id="discussionQuestion"></div>

        <div id="st-container" class="st-container st-effect-9">

            <div class='s-navbar st-menu st-effect-9' >
    <a id="switch" href="#" title="" class="btn-switch">
      <span class="bpd switch_title">BP DISORDER</span>
      <span class="mdd switch_title">MDD</span>
    </a>
    <ul>
        <li><a id='so-0' href='#' data-nav="true"><span class='clock'></span></a></li>
        <li><a id='so-1' href='#' data-nav="true"><span class='weight'></span></a></li>
        <li><a id='so-2' href='#' data-nav="true"><span class='chart'></span></a></li>
        <li><a id='so-3' href='#' data-nav="true"><span class='pill'></span></a></li>
        <li><a id='so-4' href='#' data-nav="true"><span class='isi'></span></a></li>
        <li><a id='so-5' href='#' data-nav="true"><span class='briefcase'></span></a></li>
        <li><a id='so-6' href='#' data-nav="true"><span class='wallet'></span></a></li>
        <li><a id='so-7' href='#' data-nav="true"><span class='ind'></span></a></li>
        <li><a id='so-8' href='#' data-nav="true"><span class='envelope'></span></a></li>
    </ul>
</div>
<script type="text/javascript">
    $(document).ready(function(e) {
        $('.s-navbar ul li a').on('click', function(e) {
            e.preventDefault();
            window.location.href = $(this).attr('href');
        });
    });
</script>

<div class='st-pusher'>
                <div id="s-page" class='s-content'>
                    <div id="st-trigger-effects" class="column">
                        <button data-effect="st-effect-9" class='s-logo'></button>
                    </div>

                    <style>
    #isi_x_a .patient-popup .btn-close, .x, .close-x {
        display: block;
        position: absolute;
        width: 22px;
        height: 22px;
        background-repeat: no-repeat;
        background-position: 0px -468px;
        background-image:url('assets/_global/img/sprite.png')
        top: -45px;
        margin-left: 490px;



    }
    #isi_x {
        width: 23px;
        height: 23px;
    }
    .ISI_title_popup { font-size: 19px; }

  

</style>


<div id='patient-popup-ISI' class='patient-popup pp-1' style="">
<a id="isi_x_a" href='#' title='close' class='btn-close'></a>


    <div class='content scrollable'>
        <b class="ISI_title_popup">Important Safety Information About SEROQUEL XR&reg; (quetiapine fumarate)</b>
        <p>
            <b>
            Increased Mortality in Elderly Patients with Dementia-Related Psychosis:<br />
            Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of
            death. SEROQUEL XR is not approved for the treatment of patients with dementia-related psychosis.
            </b>
        </p>
        <p>
            <b>
            Suicidal Thoughts and Behavior:<br />
            Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. SEROQUEL XR is not approved for use in pediatric patients under ten years of age.
            </b>
        </p>
        <p>
        <b>Contraindication</b><br />
        Hypersensitivity to quetiapine or to any excipients in the SEROQUEL XR formulation. Anaphylactic reactions have been reported in patients treated with SEROQUEL XR.
        </p>
        <p>
            <b>Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-Related Psychosis:</b><br />
            In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, 
            there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks), 
            including fatalities, compared to placebo-treated subjects. 
            <br>SEROQUEL XR is not approved for the treatment of patients with 
            dementia-related psychosis.
        </p>
        <p>
            <b>Neuroleptic Malignant Syndrome (NMS): </b>A potentially fatal symptom complex, sometimes referred to as NMS, has been reported in association with administration of antipsychotic drugs, including SEROQUEL XR. Rare cases of NMS have been reported with SEROQUEL XR. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. Management should include immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, intensive symptomatic treatment, and medical monitoring, and treatment of any concomitant serious medical problems.
        </p>
        <p>
            <b>Metabolic Changes:</b> <br> Atypical antipsychotic drugs have been associated with metabolic changes that include hyperglycemia/diabetes mellitus, dyslipidemia, and body weight gain. In some patients, a worsening of more than one of the metabolic parameters of weight, blood glucose, and lipids was observed in clinical studies. Changes in these metabolic profiles should be managed as
            clinically appropriate.
        </p>
        <ul class="ISI_indent">
            <li>
                <b><i>Hyperglycemia and Diabetes Mellitus:</i></b> Hyperglycemia, in some cases extreme and associated with ketoacidosis, hyperosmolar coma, or death, has been reported in patients treated with atypical antipsychotics, including SEROQUEL XR. The relationship of atypical use and glucose abnormalities is complicated by the possibility of increased risk of diabetes in the schizophrenic population and the increasing incidence of diabetes in the general population. However, epidemiological studies suggest an increased risk of treatment-emergent, hyperglycemia-related adverse reactions in patients treated with atypical antipsychotics. Patients starting treatment with atypical antipsychotics who have or are at risk for diabetes should undergo fasting blood glucose testing at the beginning of and periodically during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of the suspect drug.
            </li>
            <li>
                <b><i>Dyslipidemia:</i></b> Undesirable alterations in lipids have been observed with SEROQUEL XR use. Increases in total cholesterol, LDL-cholesterol and triglycerides, and decreases in HDL-cholesterol have been reported in clinical trials. Appropriate clinical monitoring is recommended, including fasting blood lipid testing at the beginning of and periodically during treatment.
            </li>
            <li>
                <b><i>Weight Gain:</i></b> Increases in weight have been observed in clinical trials. Patients receiving <br>SEROQUEL XR should receive regular monitoring of weight.
            </li>
        </ul>
        <p>
            <b>Tardive Dyskinesia (TD):</b> TD, a potentially irreversible syndrome of involuntary dyskinetic movements, may develop in patients treated with antipsychotic drugs. The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment and total cumulative dose of antipsychotic drugs administered to the patient increase. Although much less commonly, TD can develop after relatively brief treatment periods at low doses or even after treatment discontinuation. TD may remit, partially or completely, if antipsychotic treatment is withdrawn. SEROQUEL XR should be prescribed in a manner that is most likely to minimize the occurrence of TD, and discontinuation should be considered if signs and symptoms of TD occur.
        </p>
        <p>
            <b>Hypotension:</b> SEROQUEL XR may induce orthostatic hypotension with associated dizziness, tachycardia, and syncope, especially during the initial dose titration period and should be used with caution in patients predisposed to hypotension or with known cardiovascular or cerebrovascular disease.
        </p>
        <p>
            <b>Leukopenia, Neutropenia, and Agranulocytosis:</b> Leukopenia, neutropenia, and agranulocytosis (including fatal cases), have been reported temporally related to atypical antipsychotics, including SEROQUEL XR. Patients with a pre-existing low white blood cell (WBC) count or a history of drug-induced leukopenia/neutropenia should have their complete blood count monitored frequently during the first few months of therapy. In these patients, SEROQUEL XR should be discontinued at the first sign of a decline in WBC absent other causative factors. Patients with neutropenia should be carefully monitored, and SEROQUEL XR should be discontinued in any patient if the absolute neutrophil count is <1000/mm<sup>3</sup>.
        </p>
        <p>
            <b>Cataracts:</b> Examination of the lens by methods adequate to detect cataract formation, such as slit lamp exam or other appropriately sensitive methods, is recommended at initiation of treatment or shortly thereafter, and at 6-month intervals during chronic treatment.
        </p>
        <p>
            <b>QT Prolongation:</b> Postmarketing cases show increases in QT interval in patients who overdosed on quetiapine, in patients with concomitant illness, and in patients taking medicines known to cause electrolyte imbalance or increase the QT interval. Avoid use with drugs that increase the QT interval and in patients with risk factors for prolonged QT interval.
        </p>
        <p>
            <b>Seizures:</b> SEROQUEL XR should be used cautiously in patients with a history of seizures or with conditions that potentially lower the seizure threshold (eg, Alzheimer&rsquo;s dementia).
        </p>
        <p>
            <b>Potential for Cognitive and Motor Impairment:</b> Since SEROQUEL XR has the potential to impair judgment, thinking, or motor skills, patients should be cautioned about performing activities requiring mental alertness, such as operating a motor vehicle or operating hazardous machinery, until they are reasonably certain that SEROQUEL XR therapy does not affect them adversely.
        </p>
        <p>
            <b>Body Temperature Regulation:</b> Disruption of the body&rsquo;s ability to reduce core body temperature has been attributed to antipsychotics. Appropriate care is advised for patients who may exercise strenuously, be exposed to extreme heat, receive concomitant medication with anticholinergic activity, or be subject to dehydration.
        </p>
        <p>
            <b>Dysphagia:</b> Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Use caution in patients at risk for aspiration pneumonia. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer&rsquo;s dementia.
        </p>
        <p>
            <b>Warnings and Precautions Also Include:</b> The risk of hypothyroidism, hyperprolactinemia, and discontinuation syndrome.
        </p>
        <p>
            <b>Common Adverse Reactions:</b> The most commonly observed adverse reactions (incidence &ge;5% and twice placebo) associated with the use of SEROQUEL XR versus placebo in clinical trials for all adult indications were somnolence (25%-52% vs 9%-13%), dry mouth (12%-40% vs 1%-8%), constipation (6%-11% vs 3%-6%), dizziness (10%-13% vs 4%-11%), increased appetite (2%-12% vs 0%-6%), dyspepsia (2%-7% vs 1%-4%), weight gain (3%-7% vs 0%-1%), fatigue (3%-14% vs 2%-4%), dysarthria (2%-5% vs 0%), and nasal congestion (2%-5% vs 1%).
        </p>
        <p>
            <i><b>Please read <a href="US-SXR-CNS-PI" data-nav="true">Prescribing Information</a>, including Boxed WARNINGS.</b></i>
        </p>
        <p>
            <i>You are encouraged to report negative side effects of prescription drugs to the FDA. Visit <a id="external_link" target="_blank" href="http://www.fda.gov/medwatch" style="text-decoration: none;"><u>www.FDA.gov/medwatch</u></a> or call 1-800-FDA-1088.</i>
        </p>
        <p>
            The product information is intended for US health care professionals only.
        </p>
        <p>
            SEROQUEL XR is a registered trademark of the AstraZeneca group of companies.<br />
            &copy;2015 AstraZeneca. All rights reserved. 3086417 Last Updated 2/15
        </p>

    </div>
</div>

<div id='page-overlay' class='page-overlay'></div>

                    
<link href="../shared/assets/css/Chart_Styles.css" type="text/css" rel="stylesheet" media="all" />

<style>
    .chart-popup {
        width: 870px !important;
        margin-top: -320px;
    }
    .popup-mdd td {
        padding: 4px 50px 4px 0;
    }
    /*
    .magnifier {
        top: 272px;
        left: 704px;
    }
    #page-bpd-3 .magnifier {
        top: 254px;
        left: 704px;
    }
    #page-bpd-4 .magnifier {
        top: 0px;
        left: 704px;
    }
    */
    .EFF_BPD_pinklink {
        color: #a04670;
        text-decoration: underline;
        font-size: 14px;

    }
    #Suppes_link {
        margin-left: 21px;
    }
    #Suppes_link_2 {
        clear: both;
        display: block;
        margin-top: 14px;
    }
    #Suppes_link_3 {
        clear: both;
        display: block;
        top: -15px;
        margin-left: 20px;
    }
    #Suppes_link_4 {
        clear: both;
        display: block;
        margin-left: 20px;
    }
    .chart-pie {
        position: relative;
        top: 14px;
    }
    #baseline_MADRS {
        vertical-align: initial;
    }
    .bg-title {
        margin-bottom: 25px;
    }
    .dosing-bpd .page-bpd-page {
        background-size: 11px 31px;
    }
    .patient-popup {
        width: 525px;
    }
    .patient-popup .btn-close {
        margin-left: 518px;
    }
    .EFF_BPD_hang {
        font-family: 'AvenirNextCondensed-Regular', sans-serif;
        font-size: 13px;
        color: #6c6c6c;
        position: relative;
        top: 19px;
        left: -5px;
    }
    .list-pink li p.EFF_BPD_Last {
        margin-top: 4px;
        line-height: 1.3;
    }
    .list-pink li p.EFF_BPD_Mid {
        line-height: 1.3;
    }
    #page-bpd-4 h3 {
        margin-top: 10px;
    }
    .page4_ul {
        width: 276px;
    }
    h1 { position: relative; z-index: 100;}
    .Chart_Back {
        width: 600px;
        height: 340px;
    }
    .carousel_1 #chart-1 .arrow-right {
        left: -39px;
    }
    .magnifier {
        display: block;
        width: 32px;
        height: 32px;
        position: relative !important;
        top: -344px;
        right: -606px;
        z-index: 1;
    }
    .chart-footer {
        color: #6c6c6c;
        font-size: 13px;
        font-family: 'AvenirNextCondensed-Regular', sans-serif;
        margin-top: -39px;
    }
    .button-down {
        right: 490px;
        top: 655px;
    }
    #Suppes_link, #Suppes_link_2, #Suppes_link_4, #Suppes_link_3{
      text-decoration: underline !important;
      font-family: 'AvenirNextCondensed-DemiBold', sans-serif;
      }
    #patient-popup-7 {
        width: 658px !important;
    }
    #patient-popup-7 .btn-close, {
        margin-left: 650px !important;
    }
</style>


<!-- popup area -->
<div id='chart-popup' class='patient-popup chart-popup'> <!-- popup charts-->
    <div class='content'>
        <a href='#' title='close' class='btn-close'></a>
        <ul>
            <li id="zoom-1"><img alt='Improvement in Acute Depressive Symptoms' src="../shared/assets/img/US-SXR-CNS-Efficacy-in-BPD/chart-efficacy.png" width="850" /></li>
            <li id="zoom-2"><img alt='Improvement in Acute Depressive Symptoms' src="../shared/assets/img/US-SXR-CNS-Efficacy-in-BPD/chart-efficacy-2.png" width="850" /></li>
            <li id="zoom-3"><img alt='Improvement in Acute Depressive Symptoms' src="../shared/assets/img/US-SXR-CNS-Efficacy-in-BPD/chart-efficacy-3.png" width="850" /></li>
            <li id="zoom-4"><img alt='Improvement in Acute Depressive Symptoms' src="../shared/assets/img/US-SXR-CNS-Efficacy-in-BPD/chart-efficacy-4.png" width="850" /></li>
            <li id="zoom-5"><img alt='Improvement in Acute Depressive Symptoms' src="../shared/assets/img/US-SXR-CNS-Efficacy-in-BPD/CGI-BP-C_Zoom.jpg" width="850" /></li>
        </ul>
    </div>
</div> <!-- end popup charts -->

        <div id='patient-popup-1' class='patient-popup pp-1'> <!-- popup -->
            <div class='content'>
                <a href='#' title='close' class='btn-close'></a>
                <span class="popup_header">Reference</span>
                <ol>
                    <li><span>Suppes T, Datto C, Minkwitz M, et al. Corrigendum to “Effectiveness of the Extended Release Formulation of Quetiapine
                        as Monotherapy for the Treatment of Acute Bipolar Depression” [<i>J Affect Disord</i>. 121(1–2) (2010)106–115]. <i>J Affect Disord</i>.
                        2014;168:485-493. </span></li>
                </ol>
            </div>
        </div> <!-- end popup -->

        <div id='patient-popup-2' class='patient-popup pp-1'> <!-- popup -->
            <div class='content'>
                <a href='#' title='close' class='btn-close'></a>
                <span class="popup_header">References</span>
                <ol>
                    <li><span>Suppes T, Datto C, Minkwitz M, et al. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. <i>J Affect Disord</i>. 2010;121(1-2):106-115.</span></li>
                    <li><span>Data on file, 3017412, AstraZeneca Pharmaceuticals LP.</span></li>
                </ol>
            </div>
        </div> <!-- end popup -->

        <div id='patient-popup-3' class='patient-popup pp-1 popup-medium'> <!-- popup -->
            <div class='content'>
                <a href='#' title='close' class='btn-close'></a>
                <span class="popup_header">Clinical Global Impressions-Bipolar-Severity scale (CGI-BP-S)<sup>1</sup></span>
                <ul class="list-pink">
                    <li><span>A subscale of the CGI-BP scale based on 3 domains: overall bipolar illness, mania, and depression</span></li>
                    <li><span>Scoring reflects clinician’s impression of the patient’s clinical presentation in
                        <br>comparison to other patients seen throughout total clinical experience</span></li>
                    <li><span>CGI-BP-S scores range from 1 to 7: 1 (normal, not ill); 2 (minimally ill); 3 (mildly
                        <br>ill); 4 (moderately ill); 5 (markedly ill); 6 (severely ill); 7 (very severely ill). A
                        <br>greater decrease in the score represents more improvement</span></li>
                </ul>
                <ol>
                    <li class="text13"><span>Spearing MK, Post RM, Leverich GC, et al. Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. <i>Psychiatry Res.</i> 1997;73(3):159-171. </span></li>
                </ol>
            </div>
        </div> <!-- end popup -->


        <div id='patient-popup-8' class='patient-popup pp-1 popup-medium'> <!-- popup -->
                    <div class='content'>
                        <a href='#' title='close' class='btn-close'></a>
                        <span class="popup_header">Clinical Global Impressions-Bipolar-Change scale (CGI-BP-C)<sup>1</sup></span>
                        <ul class="list-pink">
                            <li><span>A subscale of the Clinical Global Impressions-Bipolar (BP) scale</span></li>
                            <li><span>Provides a global assessment of a patient's clinical status based on 3 domains: overall bipolar illness, mania, and depression</span></li>
                            <li><span>CGI-BP-C scores range from 1-7: 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse), 7 (very much worse)</span></li>
                        </ul>
                        <ol>
                            <li class="text13"><span>Spearing MK, Post RM, Leverich GC, et al. Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. <i>Psychiatry Res.</i> 1997;73(3):159-171.</span></li>
                        </ol>
                    </div>
                </div> <!-- end popup -->

        <div id='patient-popup-4' class='patient-popup pp-1'> <!-- popup -->
            <div class='content'>
                <a href='#' title='close' class='btn-close'></a>
                <span class="popup_header">References</span>
                <ol>
                    <li><span>Suppes T, Datto C, Minkwitz M, et al. Corrigendum to “Effectiveness of
                        the Extended Release Formulation of Quetiapine as Monotherapy for the
                        Treatment of Acute Bipolar Depression” [<i>J Affect Disord</i>. 121(1-2)
                        (2010)106-115]. <i>J Affect Disord</i>. 2014;168:485-493.</span></li>
                    <li><span>Data on file, 3017412, AstraZeneca Pharmaceuticals LP.</span></li>
                </ol>
            </div>
        </div> <!-- end popup -->

        <div id='patient-popup-5' class='patient-popup popup-medium pp-1'> <!-- popup -->
            <div class='content'>
                <a href='#' title='close' class='btn-close'></a>
                <b class="ptext16">SEROQUEL XR in Acute Depressive Episodes of Bipolar Disorder Trial</b>
                <p class="subgroups"><i>Subgroups of Patients with Bipolar I and Bipolar II Disorders</i></p>
                <p>Data from an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled monotherapy trial in the treatment of patients with depressive episodes associated with bipolar I or bipolar II disorder. Prespecified analytical statistics (<i>P</i>-values) were not conducted for Weeks 1 through 7.</p>
            </div>
        </div> <!-- end popup -->

        <div id='patient-popup-6' class='patient-popup pp-1'> <!-- popup -->
            <div class='content'>
                <a href='#' title='close' class='btn-close'></a>
                <span class="popup_header">References</span>
                <ol>
                    <li><span>Data on file, 3018500, AstraZeneca Pharmaceuticals LP.</span></li>
                    <li><span>Suppes T, Datto C, Minkwitz M, et al. Corrigendum to “Effectiveness of the Extended Release Formulation of Quetiapine as Monotherapy for the <br />Treatment of Acute Bipolar Depression” [<i>J Affect Disord</i>. 121(1-2) <br />(2010)106-115]. <i>J Affect Disord</i>. 2014;168:485-493.</span></li>
                </ol>
            </div>
        </div> <!-- end popup -->

        <div id='patient-popup-10' class='patient-popup pp-1'> <!-- popup -->
            <div class='content'>
                <a href='#' title='close' class='btn-close'></a>
                <span class="popup_header">References</span>
                <ol>
                    <li><span>Suppes T, Datto C, Minkwitz M, et al. Corrigendum to “Effectiveness of the Extended Release Formulation of Quetiapine as Monotherapy for the <br />Treatment of Acute Bipolar Depression” [<i>J Affect Disord</i>. 121(1-2) <br />(2010)106-115]. <i>J Affect Disord</i>. 2014;168:485-493.</span></li>
                    <li><span>Data on file, 2804000, AstraZeneca Pharmaceuticals LP.</span></li>
                </ol>
            </div>
        </div> <!-- end popup -->

        <div id='patient-popup-7' class='patient-popup pp-1 popup-medium'> <!-- popup patient-popup-cgi-ref -->
            <div class='content'>
                <a href='#' title='close' class='btn-close'></a>
                <span class="popup_header">References</span>
                <ol>
                    <li>
                        <span>
                            Suppes T, Datto C, Minkwitz M, et al. Corrigendum to “Effectiveness of the
                            <br>Extended Release Formulation of Quetiapine as Monotherapy for the Treatment of
                            <br>Acute Bipolar Depression” [<i>J Affect Disord</i>. 121(1-2) (2010)106-115]. <i>J Affect Disord</i>.
                            <br>2014;168:485-493.
                        </span>
                    </li>
                    <li>
                        <span>
                            Data on file, 2804000, AstraZeneca Pharmaceuticals LP.
                        </span>
                    </li>
                </ol>
            </div>
        </div> <!-- end popup -->

    <div id='patient-popup-9' class='patient-popup pp-0 popup-medium'> <!-- popup MADRS-->
    <div class='content'>
        <a href='#' title='close' class='btn-close'></a>
        <span class="popup_header">Montgomery-Åsberg Depression Rating Scale (MADRS)<sup>1</sup></span>
        <ul class="list-pink">
            <li><span>Used for the evaluation of symptoms of depression in adults and for the assessment of changes in these symptoms</span></li>
            <li><span>Each of the 10 items is rated on a scale of 0 to 6</span></li>
            <li><span>Individual item scores are added to form a Total Score</span></li>
            <li><span>Total Scores range from 0 to 60 points, with lower scores showing improvement</span></li>
        </ul>

        <br />
        <table class="popup-mdd">
            <tr><td colspan='2'><b>MADRS 10 Items</b></td></tr>
            <tr><td class="w180">Apparent sadness</td><td>Reported sadness</td></tr>
            <tr><td>Inner tension</td><td>Reduced sleep</td></tr>
            <tr><td>Reduced appetite </td><td>Concentration difficulties</td></tr>
            <tr><td>Lassitude </td><td>Inability to feel</td></tr>
            <tr><td>Pessimistic thoughts  </td><td>Suicidal thoughts</td></tr>
        </table>
        <br>

        <ol>
            <li class="text13"><span>Montgomery SA, Åsberg M. A new depression scale designed to be<br>  sensitive to change. <i>Br J Psychiatry</i>. 1979;134:382-389.</span></li>
        </ol>

    </div>
</div> <!-- end popup MADRS -->

<!-- end popup area -->



<a class="btn-people" title="" href="#"><img src="../shared/assets/img/icon-people.png"></a>
<div class="content" id="page-content">
	<div class="reveal">
		<div class="slides">
			<section class="page-bpd-page">
				<section id='page-bpd-1' class="page-bpd-page"> <!-- section 1-->
					<h1>SEROQUEL XR in acute depressive episodes of bipolar disorder trial<sup>1</sup></h1>
					<p class="subtitle">An 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled monotherapy trial
						<br />in patients with acute depressive episodes associated with bipolar I or bipolar II disorder.
					</p>

					<table class="table-pink">
						<tr>
							<td class='col-1-header'><span>Study Design</span></td>
							<td class='col-2-header'><span>Placebo (n=140)</span></td>
						</tr>
						<tr>
							<td class="col-1">
								<div class='graybox'>Randomization <i>following a screening period (up to 7 days) and washout <br />
									(up to 28 days) to discontinue psychotropic medications</i></div>
								<div class='pinkbox'>Screening and Enrollment (up to 35 days)</div>
								<div class='softpinkbox' style='margin-bottom: 10px;'>
									<i>Diagnosis at baseline</i>: Bipolar I (~80% of patients), bipolar II (~20% of
									<br>patients); rapid cycling (~27% of patients were diagnosed with rapid cycling,
									<br>defined as ≥4 but ≤8 mood episodes in the past year); patients had a mean
									<br>baseline MADRS Total Score of ~30 and a mean baseline HAM-D<sub class="fix-sub">17</sub> &nbsp;&nbsp;&nbsp;total
									<br>score of ~25
									<br>
									<p style="margin-top: 5px;">Patients were excluded from the study if they had a DSM-IV-TR diagnosis of
									<br>another Axis I disorder that was symptomatic or had required treatment
									<br>6 months prior to enrollment </p>
								</div>
							</td>

							<td class="col-2">
								<div class='gray-1'><b>Double-blind Phase</b> (8 Weeks)</div>
								<div class='gray-2'>SEROQUEL XR 300 mg/day (n=140)*
									<span>50 mg/day on Day 1<br />
										100 mg/day on Day 2<br />
										200 mg/day on Day 3<br />
										300 mg/day from Day 4  through study completion</span>
								</div>
							</td>
						</tr>
					</table>

					<div class='footer-notes-bpd'>
						<p class='text18'><i>Primary outcome measure:</i> Mean change from baseline to Week 8 in <a href="#" class="btn-open" rel="patient-popup-9" title="MADRS"><b><u>MADRS</u></b></a> Total Score compared with placebo</p>
						<p class='text18'><i>Secondary outcome measures:</i> Included change from baseline to Week 8 in <a href="#" class="btn-open" rel="patient-popup-3" title="CGI-BP-S"><b><u>CGI-BP-S</u></b></a> for overall bipolar illness; in MADRS
							<br>Total Score for Bipolar I and Bipolar II Disorders</p>
						<p class='gray-small'>*Last dose on Day 56, final assessment on Day 57.</p>
					</div>
				</section> <!-- end section 1-->

				<section id='page-bpd-2' class="page-bpd-page"> <!-- section 2-->
					<h1>Antidepressant efficacy in bipolar depression as early as Week 1 and <br />
						continuing through Week 8<sup>1</sup></h1>
					<p class="subtitle">58% reduction in mean <a href="#" class="btn-open" rel="patient-popup-9" title="MADRS"><b><u style="color:#ea519c;">MADRS</u></b></a> Total Score from baseline to Week 8 for SEROQUEL XR vs 40% for placebo<sup>2</sup></p>

					<div class="bg-title">
						<h3>SEROQUEL XR 300 mg/day delivered significant efficacy as monotherapy in acute depressive episodes <br />of bipolar disorder as early as Week 1, continuing through Week 8 (primary end point)<sup>1</sup></h3>
					</div>

					<table class="table-chart">
						<tr>
							<td>
								<img id="MADRS-BP-Depression-Suppes_Back" class="Chart_Back" src="../shared/assets/img/US-SXR-CNS-Efficacy-in-BPD/MADRS-BP-Depression-Suppes_Back.jpg" />


								<div id="step0" class="steps">
									<div style="top: 100px;">
									   <div id="slideGraph">
										  <div id="slideGraphBg">
											 <div class="vertical-line-cover">
												<div class="white-cover"></div>
												<div class="flag-box-on-line">
												   <b>Efficacy at Week 1</b>
												</div>
												<div class="black-square"></div>
												<div class="pink-circle"></div>
											 </div>
										  </div>

										  <div class="flag-box">
											<b>Efficacy at Week 1</b> continuing through Week 8
										  </div>

										  <div id="circleChart" class="circle">

											 <div class="callout-dial-wrapper-two">
												<input type="text" value="0" class="callout-dial-two" data-readOnly="true"  data-cursor="false" data-width="224" data-height="224"  data-thickness=".1" data-min="0" data-max="100" data-bgcolor="transparent" data-fgcolor="rgb(196, 38, 125)" data-displayinput="false">
											 </div>
											 <div class="callout"></div>
											 <div class="callout-text">
												<p style="-webkit-transform: scale(1.1); margin: 18px 0 8px;">
												   <span class="big-text  color-text">
												   <span class="count">58</span><sup>%</sup></span> <span class="color-text" style="margin-left:-10px; font-size: 20px;">reduction</span><br>
												   <div>
													   <span style="color:#3f3f3f;">in mean MADRS<br>
													   Total Score from baseline<br>
													   to Week 8 for </span><span class="color-text" style="color: #3f3f3f;">SEROQUEL XR</span><br>
													   <span style="color:#3f3f3f;"> vs </span><span class="medium-text bold-text" style="color:#3f3f3f;top:9px;line-height:12px;">40<sup style="font-size: 15px;vertical-align: top;position: relative;top: 0;">%</sup></span><span style="color:#3f3f3f;"> for placebo<sup>2</sup>
													   </span>
												   </div>
												</p>
											 </div>
										  </div>
									   </div>
									</div>
								 </div>


								<!-- div id="MADRS-BP-Depression-Suppes"></div>
								<img id="MADRS-BP-Depression-Suppes_Front" src="../shared/assets/img/US-SXR-CNS-Efficacy-in-BPD/MADRS-BP-Depression-Suppes_Front.png" /-->
								<a class="magnifier" title="zoom" rel='1' href="#" style="top:-680px"></a>
								<ul class='chart-footer' style="bottom: 13px; position: absolute;">
									<li id="baseline_MADRS">Baseline mean MADRS Total Score was ~30<br />
										<sup>a</sup><i>P</i><0.001 vs placebo<br />
										<i>P</i> value is based on calculation of MITT and LOCF analysis.<br>
										LS = least squares </li>
									<li>MITT = modified intention to treat<br />
										LOCF = last observation carried forward</li>
								</ul>
							</td>
							<td>
								<ul class='list-pink'>
									<li>Mean change from baseline in MADRS Total
										<br />Score at Week 8 was –17.4 with SEROQUEL XR
										<br />vs –11.9 with placebo (<i>P</i><0.001; primary end
										<br />point) in patients with bipolar depression</li>

									<li>Patients were titrated to the recommended
										<br />dose of 300 mg/day by Day 4</li>
								</ul>
								<a id="Suppes_link" href="#" onclick="Reveal.slide(0,0,0)" class="EFF_BPD_pinklink" rel="patient-popup-3" title="CGI-BP-S" href="#">Suppes et al study design</a>

							</td>
						</tr>
					</table>
				</section><!-- section 2-->

				<section id='page-bpd-3' class="page-bpd-page"> <!-- section 3-->

                    <h1>SEROQUEL XR demonstrated significant improvement in acute depressive <br />
						episodes in patients with bipolar I and bipolar II disorders at Week 8<sup>1</sup></h1>

					<div class="bg-title one-line">
                        <h3 id="subgroup-1" style="display:block;"><a href="#" class="btn-open fix-underline" rel="patient-popup-5" title="Subgroup of Patients with Bipolar I Disorder" id="chart-title">Subgroup of Patients with Bipolar I Disorder</a></h3>
                        <h3 id="subgroup-2" style="display:none;"><a href="#" class="btn-open fix-underline" rel="patient-popup-5" title="Subgroup of Patients with Bipolar II Disorder" id="chart-title">Subgroup of Patients with Bipolar II Disorder</a></h3>
					</div>
					<ul class="carousel">
						<li id='chart-1'>
							<table class="table-chart table-chart-legend">
								<tr>
									<td>
										<img id="MADRS-BPI-Subgroup-Suppes_Back" class="Chart_Back" src="../shared/assets/img/US-SXR-CNS-Efficacy-in-BPD/MADRS-BPI-Subgroup-Suppes_Back.jpg" />
										<!-- div id="MADRS-BPI-Subgroup-Suppes"></div -->
										<a class="magnifier" title="zoom" rel='3' href="#"></a>
										<ul class='chart-footer'>
											<li>Baseline mean MADRS Total Score was 30.1-30.2, MITT = modified intention to treat,<br />
												OC = observed cases, MMRM = mixed-model repeat measurement, LS=least squares</li>
											<li>
												<i>P</i> value for Week 8 based on prespecified calculation of MITT, OC, MMRM analysis.
											</li>
										</ul>
									</td>
									<td class="emptyCell45"><a href="#" title="Next" class="arrow-right" rel="1" onclick="$('#subgroup-1, #subgroup-2').toggle()"></a></td>
									<td>
										<h4>In a prespecified subgroup <br />analysis at Week 8:</h4>
										<ul class='list-pink page4_ul'>
											<li><b>Mean change from baseline</b> in
												<br />MADRS Total Score at Week 8
												<br />for patients with bipolar l
												<br />disorder receiving <b>SEROQUEL XR
												<br>was –19.7</b> vs –13.2 for
												<br />placebo (<i>P</i><0.001)<sup>1</sup></li>
											<li>Patients in the study met the
												<br />DSM-IV-TR criteria for bipolar
												<br />I or bipolar II disorder<sup>1</sup>
												<table>
													<tr>
														<td><p>-&nbsp;</p></td>
													</tr>
												</table>
											</li>
										</ul>
										<a id="Suppes_link_3" href="#" onclick="Reveal.slide(0,0,0)" class="EFF_BPD_pinklink" rel="patient-popup-3" title="CGI-BP-S" href="#">Suppes et al study design</a>
									</td>
								</tr>
							</table>
						</li>

						<li id='chart-2'>
							<table class="table-chart table-chart-legend">
								<tr>
									<td>
										<img id="MADRS-BPII-Subgroup-Suppes_Back" class="Chart_Back" src="../shared/assets/img/US-SXR-CNS-Efficacy-in-BPD/MADRS-BPII-Subgroup-Suppes_Back.jpg" />
										<!-- div id="MADRS-BPII-Subgroup-Suppes"></div -->
										<a class="magnifier" title="zoom" rel='4' href="#"></a>
										<ul class='chart-footer'>
											<li>Baseline mean MADRS Total Score was 28.1-30.3, MITT = modified intention to treat,<br />
												OC = observed cases, MMRM = mixed-model repeat measurement, LS = least squares</li>
											<li><i>P</i> value for Week 8 based on prespecified calculation of MITT, OC, MMRM analysis.</li>
										</ul>
									</td>
									<td class="emptyCell45"><a href="#" title="Next" class="arrow-right" rel="2" onclick="$('#subgroup-1, #subgroup-2').toggle()"></a></td>
									<td>
										<h4>In a prespecified subgroup <br />analysis at Week 8:</h4>
										<ul class='list-pink page4_ul'>
											<li><b>Mean change from baseline</b> in
												<br />MADRS Total Score at Week 8 for
												<br />patients with bipolar ll disorder
												<br />receiving <b>SEROQUEL XR was</b>
												<br /><b>–19.3</b> vs –15 for placebo (<i>P</i><0.05)<sup>1</sup></li>

											<li>Patients in the study met the
												<br />DSM-IV-TR criteria for bipolar
												<br />I or bipolar II disorder<sup>1</sup>
											</li>
										</ul>
										<a id="Suppes_link_4" href="#" onclick="Reveal.slide(0,0,0)" class="EFF_BPD_pinklink" rel="patient-popup-3" title="CGI-BP-S" href="#">Suppes et al study design</a>
									</td>
								</tr>
							</table>
						</li>
					</ul>
				</section> <!-- section 3-->

				<section id='page-bpd-4' class="page-bpd-page"> <!-- section 4 -->

                    <div id="title-1" style="display: block;">
                    <h1>SEROQUEL XR significantly improved <a href="#" class="btn-open" rel="patient-popup-3" title="CGI-BP-C">CGI-BP-S Scale</a> at Week 8<sup>1,2</sup></h1>

                    <div class="bg-title">
                    <h3>SEROQUEL XR 300 mg/day led to significant improvements in CGI-BP-S for overall depression</h3>
                    </div>
                    </div>

                    <div id="title-2" style="display: none;">
                    <h1>SEROQUEL XR significantly improved <a href="#" class="btn-open" rel="patient-popup-8" title="CGI-BP-C">CGI-BP-C Scale</a> at Week 8<sup>1,2</sup></h1>

                    <div class="bg-title">
                    <h3>SEROQUEL XR 300 mg/day led to significant improvement in CGI-BP-C for overall clinical status</h3>
                    </div>
                    </div>

					<ul class="carousel carousel_1">
						<li id='chart-1'>
							<table class="table-chart">
								<tr>
									<td>
										<img id="CGI-S-Suppes_Back"  class="Chart_Back" src="../shared/assets/img/US-SXR-CNS-Efficacy-in-BPD/CGI-S-Suppes_Back.jpg" />
										<!-- div id="CGI-S-Suppes"></div -->
										<a class="magnifier" title="zoom" rel='2' href="#"></a>
									</td>
									<td class="emptyCell45"><a href="#" onclick="$('#title-1, #title-2').toggle();$('#ref').attr('rel', 'patient-popup-6');" title="Next" class="arrow-right" rel="1"></a></td>
									<td>
										<ul class='list-pink'>
											<li>In this prespecified secondary end
												<br />point, mean improvements in
												<br />CGI-BP-S scores for both depression
												<br />and overall bipolar illness (not shown
												<br />on graph) from baseline to Week 8
												<br />were significant for SEROQUEL XR
												<br />compared with placebo (<i>P</i><0.001)<sup>2*</sup></li>

											<li>Mean changes in CGI-BP-S for mania
												<br />from baseline to Week 8 were not
												<br />significantly different between
												<br />SEROQUEL XR and placebo (<i>P</i>=NS)<sup>2</sup>

												<a id="Suppes_link_2" href="#" onclick="Reveal.slide(0,0,0);" class="EFF_BPD_pinklink" title="CGI-BP-S">Suppes et al study design</a>

												<p class="EFF_BPD_Mid">CGI-BP-S = Clinical Global
													<br />Impressions-Bipolar-Severity of Illness
													<br />MITT = modified intention to treat
													<br />LOCF = last observation carried forward
													<br />NS = not significant</p>

												<span class="EFF_BPD_hang">*</span>
												<p class="EFF_BPD_Last">Prespecified analytical statistics (<i>P</i> values) were<br />
													not conducted for Weeks 1 through 7.</p>
											</li>
										</ul>
									</td>
								</tr>
							</table>
						</li>

						<li id='chart-2'>
                            <table class="table-chart table-chart-legend">
								<tr>
									<td>
										<img id="CGI-BP-C_Back" class="Chart_Back" src="../shared/assets/img/US-SXR-CNS-Efficacy-in-BPD/CGI-BP-C_Back.jpg" />
										<!-- no animated chart built -->
										<a class="magnifier" title="zoom" rel='5' href="#"></a>
										<ul class='chart-footer'>
											<li><span><sup>a</sup> <i>P</i><0.001 vs placebo.</span></li>


										</ul>
									</td>
									<td class="emptyCell45"><a href="#" onclick="$('#title-1, #title-2').toggle();$('#ref').attr('rel', 'patient-popup-10');" title="Next" class="arrow-right" rel="2"></a></td>

									</td>
									<td>
										<ul class='list-pink'>
											<li>In the bipolar depression trial,
												<br><b>63.2% of patients taking
												<br>SEROQUEL XR</b> received ratings
												<br>using the CGI-BP-C of "much
												<br>improved" or "very much
												<br>improved" at Week 8, vs 39.4%
												<br>with placebo (<i>P</i><0.001)<sup>1,2*</sup>
											</li>

											<li>Mean CGI-BP-C scores for mania
												<br>at Week 8 were not significantly
												<br>different between SEROQUEL XR
												<br>and placebo (<i>P</i>=NS)<sup>1</sup>

												<a id="Suppes_link_2" href="#" onclick="Reveal.slide(0,0,0);"class="EFF_BPD_pinklink" title="CGI-BP-S" href="#">Suppes et al study design</a>

												<p class="EFF_BPD_Mid">CGI-BP-C = Clinical Global
													<br />Impressions-Bipolar-Change
													<br />MITT = modified intention to treat
													<br />LOCF = last observation carried forward
													<br />NS = not significant</p>

												<span class="EFF_BPD_hang">*</span>
												<p class="EFF_BPD_Last">Prespecified analytical statistics (<i>P</i> values) were<br />
													not conducted for Weeks 1 through 7.</p>
											</li>
										</ul>
									</td>
								</tr>
							</table>
						</li>
					</ul>
				</section><!-- section 4 -->
			</section>
		</div>
	</div>
</div>
<a id="next-slide" href='#' title='Go to' class='button-down'></a>

<script type="text/javascript" src="../shared/assets/js/jquery.knob.js"></script>
<script type="text/javascript" src="../shared/assets/js/jquery.roundabout.min.js" ></script>
<script type="text/javascript" src="../shared/assets/js/chart-animation.js"></script>
<script type="text/javascript">

    var slide = 1;

    $(document).ready(function () {
        $('#ref').attr('rel', 'patient-popup-1');
        Reveal.initialize({
            /*touch: false,*/
            controls: false,
            progress: false,
            transition: 'slide',
            minScale: 1,
            maxScale: 1
        });

        Reveal.addEventListener('slidechanged', function (  ) {
            $('#next-slide').css('display', 'block');
            if(Reveal.getState().indexv == '3') {
                $('#next-slide').css('display', 'none');
            }

            var state = Reveal.getState();
            switch(state.indexv) {
                case 0: $('#ref').attr('rel', 'patient-popup-1'); break;
                case 1:
                	$('#ref').attr('rel', 'patient-popup-4');
                	setTimeout(function(){gotFocus();},2000);
					break;
                case 2: $('#ref').attr('rel', 'patient-popup-7'); break;
                case 3: $('#ref').attr('rel', 'patient-popup-10'); break;
            }
        });

        Reveal.addEventListener('ready', function (event) {
            checkForDeepLink.then(function(result){

			//Make sure it works
			console.log('Deep Link: ' + result);

			//Do something with the link
			switch(result) {
				case 'bpd_madrs_set':
					Reveal.slide(0,1,0);
					setTimeout(function(){gotFocus();},2000);
				break;
				case 'bpd_cgi_set':
					Reveal.slide(0,3,0 );
				break;
				case 'bpd_subgroup_set':
					Reveal.slide( 0,2,0 );
				break;
			}

			});
    	});



        $('#next-slide').on('click', function (e) {
            e.preventDefault();
            Reveal.next();
        });



        var carousel = $('.carousel').roundabout({
            btnNext: ".arrow-right",
            minScale: 0.95,
            minOpacity: 0,
        });


    });
</script>

</div>
            </div>
        </div>

        
<link rel="stylesheet" href="../shared/assets/css/footer.css">


<div id="footer_main" class='s-footer'>
    <div class="content">
        <p><b>Important Safety Information About SEROQUEL XR&reg; (quetiapine fumarate)</b>
            <br>Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Elderly patients with dementia-related psychosis
            <br>treated with antipsychotic drugs are at an increased risk of death. SEROQUEL XR is not approved for the treatment of patients
            <br>with dementia-related psychosis. &nbsp;<a title='MORE' href='#' class='btn-open' rel='patient-popup-ISI'><u>MORE</u></a><br />
            <i>Please read Important Safety Information and</i> <a  class="pi_ital" href='#' onclick="navigateTo('US-SXR-CNS-PI')" title='Prescribing Information'><u>Prescribing Information</u></a>, <i>including Boxed WARNINGS</i>.</p>
    </div>

    <div class='footer-right-content'>
        <a class="logo-seroquel" href='#' title='Once daily - SEROQUEL XR - quetiapine fumarate - extended-release tablets'><img src="../shared/assets/img/logo-seroquel.png" /></a>
        <ul>
            <li><a id='isi' href="#" title="ISI"  class='btn-open' rel='patient-popup-ISI'>ISI</a></li>
            <li><a id='pi' href="#" title="PI" onclick="navigateTo('US-SXR-CNS-PI')">PI</a></li>
            <li><a id='ref' href="#" title="REF" class='btn-open' rel='patient-popup'>REF</a></li>
        </ul>
    </div>
</div>

<div id="dynamicNav">&nbsp;</div>

    </body>
        <script type="text/javascript" src="../shared/assets/js/veeva-library-4.0.js"></script>
        <script type="text/javascript" src="../shared/assets/js/veeva_helper.js"></script>
        <script type="text/javascript" src="../shared/assets/js/veeva_boilerplate.js"></script>
        <script type="text/javascript" src="../shared/assets/js/reveal.js"></script>
        <script type="text/javascript" src="../shared/assets/js/main.js"></script>
        <script type="text/javascript" src="../shared/assets/js/fastclick.min.js"></script>
        <script type="text/javascript" src="../shared/assets/js/classie.js"></script>
        <script type="text/javascript" src="../shared/assets/js/sidebarEffects.js"></script>
        <script type="text/javascript" src="../shared/assets/js/iscroll5.js"></script>
        <script type="text/javascript" src="../shared/assets/js/deviceOrientation.js"></script>
        <script>

            if ('addEventListener' in document) {
                document.addEventListener('DOMContentLoaded', function() {
                    FastClick.attach(document.body);
                }, false);
            }

            $.get( "../shared/partials/toolkit.html", function( data ) {
                $('#dynamicNav').html(data);
                setupiRepNavigation();
                console.log( "Dynamic load of TOOLKIT was performed." );
            });

    	</script>
</html>



